“Beyond PD-1/PD-L1: TME-Targeted Therapies in the Era of Immunotherapy Resistance” (2026) Journal of Biomolecules, Pathogenesis and Therapeutics, 2(1), pp. 1–3. doi:10.68041/jbpt.v2i1/06.